We are keen to increase awareness about the processes and complexity of collecting biospecimens
In this article, the authors report two patients with advanced NSCLC harboring an STK11/LKB1 mutations who presented a complete response to nivolumab treatement.
Ernest Nadal, Simon Heeke, Jonathan Benzaquen, Noelia Vilariño, Arturo Navarro, Daniel Azuara, Mar Varela, Josiane Otto, Nuria Baixeras, David Shahbazian, Pascal Puchois, Sarah E. Church, Thomas H. Smith, Elisabeth Lanteri, Marius Ilié, Paul Hofman
Correspondence in Nature Medicine
By Paul Hofman, Pascal Puchois, Patrick Brest, Hicham Lahlou and Daniel Simeon-Dubach
Trans-Hit Bio White Paper
Vanessa Tumilasci, Peter M. Nowacki, Pascal Puchois
Users agree that biobanks aren’t delivering – but what’s wrong, and how can it be fixed?
By Vanessa Tumilasci, Project Management and Communications, Trans-Hit Biomarkers Inc., Laval, Canada
November 2017
Dominic Allen’s article (1), “A Failed Model,” highlights some of the reasons why biobanks are failing to provide the...
Transparency regarding the source of biospecimens would improve research quality, reproducibility, and translational use of acquired knowledge. Scientific robust publications, dissemination and communication are central to this-as are the regulatory reporting guidelines in play.
Chapter 3 - Introduction: The Cardinal Role of Biobanks and Human Biospecimen Collections in Biomarker Validation: Issues Impeding Impact of Biomarker Research Outcomes
A recent news story in Nature Medicine (19, 253, 2013) proposed a number of solutions to the problem of sample underuse in biospecimen repositories, but the article failed to address one imporant source of underuse: the lack of access to biobank resources by reserachers working in the biomedical industry.